Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia.
- Published Article
- Publication Date
Jan 01, 1999
Immunocytochemistry was used to analyze the expression of the Fas ligand (FasL) in sixty-four children with newly diagnosed acute lymphoblastic leukemia (ALL). FasL expression was detected in 55 of 64 children (86%). Children with newly diagnosed ALL and FasL expression exhibited longer relapse-free and overall survival times under chemotherapy than did patients who did not express the Fas ligand. These data suggest that Fas/FasL mediated signaling may play a general role in the cytotoxicity of anticancer drugs.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/02/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/10629626